Overview

A Phase 1a/1b First-in-human Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With a PD-1 Monoclonal Antibody in Advanced Solid Tumors

Status:
Not yet recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn about IOS-1002 in patients with solid tumors. The main questions it aims to answer are: - To determine the safety and tolerability of various doses of IOS-1002 administered alone and/or in combination with a PD-1 Antibody in a single dose escalation scheme - To determine the safety, tolerability and efficacy of a selected dose of IOS-1002 administered every 2 weeks alone and in combination with a PD-1 Antibody The study will be conducted in 3 parts: - Part A (Phase 1a, monotherapy and combination therapy dose escalation): IOS-1002 alone and IOS-1002 plus PD-1 mAb in patients with advanced solid tumors - Part B (Phase 1b, monotherapy cohort expansion): IOS-1002 alone in patients with advanced solid tumors - Part C (Phase 1b, combination therapy cohort expansion): IOS-1002 plus PD-1 mAb in patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
ImmunOs Therapeutics AG